Targeted Strategies for Today's Evolving Markets

MissionIR Blog

TapImmune, Inc. (TPIV.OB) Signs License Agreement with Crucell (CRXL)

TapImmune Inc., best known for developing immunotherapeutic vaccines for cancer and infectious diseases, announced recently that it has signed a license agreement with Crucell N.V. (NASDAQ: CRXL), a global biopharmaceutical company based in the Netherlands. The license allows TapImmune to use Crucell’s proprietary PER.C6® cells in its development programs.

The cell line is ideal for the development and large-scale production of a wide variety of biopharmaceuticals. Specifically, PER.C6 cells do not generate replication competent adenoviruses in the use of recombinant vaccines using adenoviral vectors, making it excellent for the production of adenoviral vectors for clinical applications. Generally, the PER.C6 cell line is the best documented line for vaccine development to date. Its extensive Biologics Master File at the U.S. FDA can be cross-referenced by licensees, resulting in simplification and acceleration of the IND filing and approval process.

The agreement is important for the production of TapImmune’s vaccine products. TapImmune’s primary product candidate, the AdhTAP vaccine enhancer, is designed to help the body’s immune system identify cancer cells so that it can destroy them. It does this by restoring and augmenting antigen presentation and subsequent recognition and killing of cancer cells by the immune system. TapImmune is currently planning for the commencement of clinical manufacturing and toxicology studies.

TapImmune is also developing a TAP based prophylactic vaccine, which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by as much as 1,000 times. As a vaccine, TAP technology could be significant in the fight against many pandemic infectious diseases. As a cancer therapy, TAP vaccine could prove to be a key component in a more successful assault on cancer.

The partnership between TapImmune and Crucell also gives Crucell the right to negotiate a license for TapImmune’s TAP technologies for infectious disease indications.

Let us hear your thoughts: TapImmune, Inc. Message Board

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *